The dark side of extracellular ATP in kidney diseases

Anna Solini, Vera Usuelli, Paolo Fiorina

Research output: Contribution to journalArticle

Abstract

Intracellular ATP is the most vital source of cellular energy for biologic systems, whereas extracellular ATP is a multifaceted mediator of several cell functions via its interaction, in an autocrine or paracrine manner, with P2 purinergic receptors expressed on the cell surface. These ionotropic and metabotropic P2 purinergic receptors modulate a variety of physiologic events upon the maintenance of a highly sensitive "set point," the derangement of which may lead to the development of key pathogenic mechanisms during acute and chronic diseases. Growing evidence suggests that extracellular ATP signaling via P2 purinergic receptors may be involved in different renal pathologic conditions. For these reasons, investigators and pharmaceutical companies are actively exploring novel strategies to antagonize or block these receptors with the goal of reducing extracellular ATP production or accelerating extracellular ATP clearance. Targeting extracellular ATP signaling, particularly through the P2X7 receptor, has considerable translational potential, given that novel P2X7-receptor inhibitors are already available for clinical use (e.g., CE224,535, AZD9056, and GSK1482160). This review summarizes the current evidence regarding the involvement of extracellular ATP and its P2 purinergic receptor-mediated signaling in physiologic and pathologic processes in the kidney; potential therapeutic options targeting extracellular ATP purinergic receptors are analyzed as well.

Original languageEnglish
Pages (from-to)1007-1016
Number of pages10
JournalJournal of the American Society of Nephrology
Volume26
Issue number5
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Kidney Diseases
Purinergic P2 Receptors
Adenosine Triphosphate
Purinergic P2X7 Receptors
Kidney
Purinergic Receptors
Acute Disease
Pathologic Processes
Chronic Disease
Maintenance
Research Personnel
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Nephrology

Cite this

The dark side of extracellular ATP in kidney diseases. / Solini, Anna; Usuelli, Vera; Fiorina, Paolo.

In: Journal of the American Society of Nephrology, Vol. 26, No. 5, 01.05.2015, p. 1007-1016.

Research output: Contribution to journalArticle

Solini, Anna ; Usuelli, Vera ; Fiorina, Paolo. / The dark side of extracellular ATP in kidney diseases. In: Journal of the American Society of Nephrology. 2015 ; Vol. 26, No. 5. pp. 1007-1016.
@article{2e370aef51d04a18bf1b3c3315a4f61c,
title = "The dark side of extracellular ATP in kidney diseases",
abstract = "Intracellular ATP is the most vital source of cellular energy for biologic systems, whereas extracellular ATP is a multifaceted mediator of several cell functions via its interaction, in an autocrine or paracrine manner, with P2 purinergic receptors expressed on the cell surface. These ionotropic and metabotropic P2 purinergic receptors modulate a variety of physiologic events upon the maintenance of a highly sensitive {"}set point,{"} the derangement of which may lead to the development of key pathogenic mechanisms during acute and chronic diseases. Growing evidence suggests that extracellular ATP signaling via P2 purinergic receptors may be involved in different renal pathologic conditions. For these reasons, investigators and pharmaceutical companies are actively exploring novel strategies to antagonize or block these receptors with the goal of reducing extracellular ATP production or accelerating extracellular ATP clearance. Targeting extracellular ATP signaling, particularly through the P2X7 receptor, has considerable translational potential, given that novel P2X7-receptor inhibitors are already available for clinical use (e.g., CE224,535, AZD9056, and GSK1482160). This review summarizes the current evidence regarding the involvement of extracellular ATP and its P2 purinergic receptor-mediated signaling in physiologic and pathologic processes in the kidney; potential therapeutic options targeting extracellular ATP purinergic receptors are analyzed as well.",
author = "Anna Solini and Vera Usuelli and Paolo Fiorina",
year = "2015",
month = "5",
day = "1",
doi = "10.1681/ASN.2014070721",
language = "English",
volume = "26",
pages = "1007--1016",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "5",

}

TY - JOUR

T1 - The dark side of extracellular ATP in kidney diseases

AU - Solini, Anna

AU - Usuelli, Vera

AU - Fiorina, Paolo

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Intracellular ATP is the most vital source of cellular energy for biologic systems, whereas extracellular ATP is a multifaceted mediator of several cell functions via its interaction, in an autocrine or paracrine manner, with P2 purinergic receptors expressed on the cell surface. These ionotropic and metabotropic P2 purinergic receptors modulate a variety of physiologic events upon the maintenance of a highly sensitive "set point," the derangement of which may lead to the development of key pathogenic mechanisms during acute and chronic diseases. Growing evidence suggests that extracellular ATP signaling via P2 purinergic receptors may be involved in different renal pathologic conditions. For these reasons, investigators and pharmaceutical companies are actively exploring novel strategies to antagonize or block these receptors with the goal of reducing extracellular ATP production or accelerating extracellular ATP clearance. Targeting extracellular ATP signaling, particularly through the P2X7 receptor, has considerable translational potential, given that novel P2X7-receptor inhibitors are already available for clinical use (e.g., CE224,535, AZD9056, and GSK1482160). This review summarizes the current evidence regarding the involvement of extracellular ATP and its P2 purinergic receptor-mediated signaling in physiologic and pathologic processes in the kidney; potential therapeutic options targeting extracellular ATP purinergic receptors are analyzed as well.

AB - Intracellular ATP is the most vital source of cellular energy for biologic systems, whereas extracellular ATP is a multifaceted mediator of several cell functions via its interaction, in an autocrine or paracrine manner, with P2 purinergic receptors expressed on the cell surface. These ionotropic and metabotropic P2 purinergic receptors modulate a variety of physiologic events upon the maintenance of a highly sensitive "set point," the derangement of which may lead to the development of key pathogenic mechanisms during acute and chronic diseases. Growing evidence suggests that extracellular ATP signaling via P2 purinergic receptors may be involved in different renal pathologic conditions. For these reasons, investigators and pharmaceutical companies are actively exploring novel strategies to antagonize or block these receptors with the goal of reducing extracellular ATP production or accelerating extracellular ATP clearance. Targeting extracellular ATP signaling, particularly through the P2X7 receptor, has considerable translational potential, given that novel P2X7-receptor inhibitors are already available for clinical use (e.g., CE224,535, AZD9056, and GSK1482160). This review summarizes the current evidence regarding the involvement of extracellular ATP and its P2 purinergic receptor-mediated signaling in physiologic and pathologic processes in the kidney; potential therapeutic options targeting extracellular ATP purinergic receptors are analyzed as well.

UR - http://www.scopus.com/inward/record.url?scp=84929308094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929308094&partnerID=8YFLogxK

U2 - 10.1681/ASN.2014070721

DO - 10.1681/ASN.2014070721

M3 - Article

C2 - 25452669

AN - SCOPUS:84929308094

VL - 26

SP - 1007

EP - 1016

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 5

ER -